Adenoviral mediated transduction of adenoid cystic carcinoma by human TRAIL gene driven with hTERT tumor specific promoter induces apoptosis

Cancer Biology and Therapy

Volumn 8, Issue 10, 2009, Pages 966-972

  Zang, Guangxiang ^a   Miao, Leiying ^a   Mu, Yabing ^a   Qiao, Chunyan ^a   Liu, Jinzhong ^a   Ke, Xiaoliang ^a   Zheng, Changyu ^b   Sun, Hongchen ^a  

^a JILIN UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Adenoid cystic carcinoma; Gene therapy; hTERT promoter; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; PHOSPHATE BUFFERED SALINE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADENOID CYSTIC CARCINOMA; ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NITROBLUE TETRAZOLIUM TEST; PROMOTER REGION; SALIVARY GLAND; TUMOR VOLUME;

ADENOVIRIDAE; APOPTOSIS; CARCINOMA, ADENOID CYSTIC; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FORMAZANS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; PROMOTER REGIONS, GENETIC; SALIVARY GLAND NEOPLASMS; TELOMERASE; TETRAZOLIUM SALTS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 68049137584     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.10.8117     Document Type: Article

References (52)

1. Tomich CE. Adenoid cystic carcinoma. In: Ellis GE, Auclair PL, Gnepp DR, eds. Surgical Pathology of the salivary glands. W.B. Saunders: Philadelphia 1991; 333-49.
2. Peel RL, Gnepp DR. Disease of the salivary glands. In: Barnes L, ed. Surgical pathology of the head and neck. Dekker: New York 1985; 533-45.
3. Spiers AS, Esseltine DL, Ruckdeschel JC, Davies JN, Horton J. Metastatic adenoid cystic carcinoma of salivary glands: case reports and review of the literature. Cancer Causes Control 1996; 3:336-42.
4. Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the eastern cooperative oncology group. Head Neck 2006; 28:197-204.
5. Whatley WS, Thompson JW, Rao B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg 2006; 134:385-8.
6. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6:335-46.
7. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3.
8. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis mediating-receptor for TRAIL. EMBO J 1997; 16:5386-97.
9. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, Dubose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70.
10. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4induces NFkappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20.
11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7.
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63.
13. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003; 63:2369-72.
14. Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 2004; 10:3535-41.
15. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res 2002; 62:3093-9.
16. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90.
17. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
18. Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Therapy 2006; 13:330-8.
19. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61:3330-8.
20. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165:2886-94.
21. Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, et al. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 2003; 22:1241-5.
22. Gu J, Kagawa S, Takakura M, Kyo S, Inouse M, Roth JA, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60:5359-64.
23. Hodes R. Molecular targeting of cancer: telomeres as targets. Proc Natl Acad Sci USA 2001; 98:7649-51.
24. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, et al. A novel telomerase-specific gene therapy:gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000; 11:1397-406.
25. Gu J, Fang B. Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2003;2:64-70.
26. Song MS, Lee SW. Cancer-selective induction of cytotoxicity by tissue-specific expression of targeted trans-splicing ribozyme. FEBS Letters 2006; 580:5033-43.
27. Jacob D, Davis J, Zhang L, Zhu H, Teraishi F, Fang BL. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12:109-15.
28. Su CQ, Wang XH, Chen J, Liu YJ, Wang WG, Li LF. Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma. World J Gastroenterol 2006; 12:7613-20.
29. Voortman J, Resende TP, Abou El, Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6:2103-12.
30. VanOosten RL, Earel JK Jr, Griffith TS. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 2007; 12:561-71.
31. Engesaeter BØ, Bonsted A, Lillehammer T, Engebraaten O, Berg K, Maelandsmo GM. Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines. Cancer Biol Ther 2006; 5:1511-20.
32. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, et al. Mesenchymal Stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008; 12:2628-43.
33. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 2007; 67:8783-90.
34. Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 2007; 304:315-23.
35. Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 2008; 14:2813-23.
36. Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci 2008; 82:1154-61.
37. Wack S, Rejiba S, Parmentier C, Aprahamian M, Hajri A. Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther 2008; 16:252-60.
38. Pan Q, Liu B, Liu J, Cai R, Liu X, Qian C. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol 2008; 47:135-44.
39. Dong A, Hu J, Zhao L, Xu H, Liu X. Regulation and pharmacokinetics of inducible recombinant TRAIL expression. Cancer Biol Ther 2007; 6:1978-85.
40. Ray S, Paulmurugan R, Patel MR, Ahn BC, Wu L, Carey M, et al. Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy. Mol Ther 2008; 16:1848-56.
41. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008; 7:2034-8.
42. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N, et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9:496-509.
43. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564-7.
44. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-60.
45. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann T, Wendling U, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000; 356:827-8.
46. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7:383-5.
47. Nagata S. Steering anti-cancer away from the TRAIL. Nature Med 2000; 6:502-3.
48. Zhang X, Cheung RM, Komaki R, Fang B, Chang JY. Radiotherapy sensitization by tumor-specific TRAIL-gene targeting improves survival of mice bearing human nonsmall cell lung cancer. Clin Cancer Res 2005; 11:6657-68.
49. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. In: Roth MG, Ed. Methods in Cell Biology. San Diego: California 1994; 161-89.
50. Zheng C, Baum BJ, Iadarola MJ, O'Connell BC. Genomic integration and gene expression by a modified adenoviral vector. Nat Biotech 2000; 18:176-80.
51. Zuo X , Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, et al. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 2006; 25:1225-41.
52. Yang YJ, Zhu J, Fu HJ, Sun ZX, Zheng XF. Specific expression of hTERT promoter driving caspase 3 gene and its anti-cancer activity. Bull Acad Mil Med Sci 2005; 29:116-9.